<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014702</url>
  </required_header>
  <id_info>
    <org_study_id>52-00006-000</org_study_id>
    <nct_id>NCT01014702</nct_id>
  </id_info>
  <brief_title>Prospective Clinical Trial of the LensAR Laser System</brief_title>
  <official_title>Prospective Clinical Trial of the LensAR Laser System in the Treatment of Cataracts of Different Grades of Maturity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LensAR Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LensAR Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The LensAR Laser System is used to create an opening in the anterior capsule of the lens and
      fragments the cataractous lens. The study will evaluate clinical outcomes compared to the
      contra-lateral eye treated with conventional phacoemulsification surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completeness and ease of opening of capsulotomy</measure>
    <time_frame>Day 0 (Surgery)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduced need for ultrasound phacoemulsification compared to control eye</measure>
    <time_frame>Day 0 (surgery)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Laser Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phacoemulsifcation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LensAR Laser System</intervention_name>
    <description>Use of laser for capsulotomy and lens fragmentation</description>
    <arm_group_label>Laser Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional phacoemulsification</intervention_name>
    <description>Use of standard techniques for capsulotomy and lens fragmentation</description>
    <arm_group_label>Phacoemulsifcation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must sign and be given a copy of the written informed consent form

          -  Subjects must have elected to undergo lens extraction and IOL implantation and then
             elect to have the LensAR laser surgery as part of the procedure.

          -  Subjects must be willing and able to return for scheduled follow-up examinations for 6
             months after surgery.

          -  Subjects must have central 7 mm of clear cornea without vascularization.

        Exclusion Criteria:

          -  Subjects who have undergone previous corneal or intraocular surgery in the eye to be
             treated.

          -  Subjects with a history, signs or symptoms of ocular disease or atypical finding which
             would be contraindicated under standard of care for cataract surgery.

          -  Diabetic or hypertensive subjects with clinical evidence of retinal pathology.

          -  Subjects with macular degenerative pathology.

          -  Subjects with a history of steroid-responsive rise in IOP or uncontrolled glaucoma in
             either eye.

          -  Subjects with known lens/zonular instability such as, but not restricted to, Marfan's
             Syndrome, Pseudoexfoliation Syndrome, etc.

          -  Subjects with corneal disease or pathology that precludes applanation of the cornea or
             transmission of laser wavelength or distortion of laser light.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asociacion para Evitar la Ceguera en Mexico IAP</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2009</study_first_submitted>
  <study_first_submitted_qc>November 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2009</study_first_posted>
  <last_update_submitted>April 14, 2011</last_update_submitted>
  <last_update_submitted_qc>April 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Keith Edwards, Director Clinical &amp; Regulatory Affairs</name_title>
    <organization>LensAR Incorporated</organization>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Capsulotomy</keyword>
  <keyword>Capsulorrhexis</keyword>
  <keyword>lens fragmentation</keyword>
  <keyword>phacoemulsification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

